Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Q4 2025 revenue rises 9% to $284 million; 2026 guidance $1.22-$1.28 billion

Positive Impact 3 of 5 earnings Written later

Acadia Pharmaceuticals reported fourth-quarter 2025 GAAP revenue of $284 million, up 9% from a year earlier, and full-year 2025 GAAP revenue of $1.07 billion, up 12%. Fourth-quarter net income was $274 million, or $1.60 per diluted share, but it included a non-cash income tax benefit of $250 million, and GAAP NUPLAZID sales were reduced by a $20 million change in estimate for Inflation Reduction Act rebates. The company also issued full-year 2026 GAAP revenue guidance of $1.22 to $1.28 billion.

Key points

  • Q4 2025 GAAP total revenues were $284 million, up from $259.6 million in Q4 2024; FY 2025 revenues were $1.07 billion, up 12%.
  • Q4 2025 net income was $274 million, or $1.60 per diluted share, versus $144 million, or $0.86, a year earlier; the quarter included a $250 million non-cash tax benefit.
  • Q4 2025 GAAP NUPLAZID net sales were $174 million, including a $20 million IRA rebate change in estimate; non-GAAP adjusted sales were $189 million.
  • 2026 GAAP guidance: total revenues of $1.22 to $1.28 billion, NUPLAZID net sales of $760 to $790 million, DAYBUE net sales of $460 to $490 million.

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECFeb 25, 2026, 4:20 PM ET
Accession number0001193125-26-071674

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.